Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

160.72USD
16 Feb 2018
Change (% chg)

$-0.22 (-0.14%)
Prev Close
$160.94
Open
$160.85
Day's High
$162.07
Day's Low
$159.49
Volume
452,036
Avg. Vol
584,252
52-wk High
$174.60
52-wk Low
$84.39

Chart for

About

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $39,103.64
Shares Outstanding(Mil.): 252.12
Dividend: --
Yield (%): --

Financials

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

14 Feb 2018

UPDATE 1-U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

13 Feb 2018

U.S. FDA approves Vertex cystic fibrosis combination treatment

Feb 12 The U.S. Food and Drug administration on Monday approved a treatment for cystic fibrosis that combines Vertex Pharmaceuticals Inc's Kalydeco with another medicine, Vertex said, marking the company's third product for the life-shortening lung disorder.

13 Feb 2018

BRIEF-Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis

* VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK)

13 Feb 2018

BRIEF-Vertex Pharma Says FDA Approved SYMDEKO For Treating Underlying Cause Of Cystic Fibrosis

* VERTEX PHARMACEUTICALS INC - FDA APPROVED SYMDEKO FOR TREATING UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER​

13 Feb 2018

Vertex picks cystic fibrosis triple combos for Phase III trials

Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

01 Feb 2018

Vertex picks cystic fibrosis triple combos for Phase III trials

Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

01 Feb 2018

UPDATE 1-Vertex picks cystic fibrosis triple combos for Phase III trials

Jan 31 Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

01 Feb 2018

BRIEF-Vertex Pharmaceuticals Reports Q4 Shr of $0.39

* VERTEX PHARMACEUTICALS - QTRLY EARNINGS PER SHARE $0.39; QTRLY NON-GAAP EARNINGS PER SHARE $0.61; QTRLY TOTAL REVENUES $651.6 MILLION VERSUS $458.7 MILLION

01 Feb 2018

Vertex picks cystic fibrosis triple combinations for Phase III trials

Jan 31 Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

01 Feb 2018

Competitors

Earnings vs. Estimates